




Instance: composition-en-d9e1f5caf32113b1e6722af1d88782c1
InstanceOf: CompositionUvEpi
Title: "Composition for pifeltro Package Leaflet"
Description:  "Composition for pifeltro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/18/1332/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd9e1f5caf32113b1e6722af1d88782c1)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - pifeltro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Pifeltro is and what it is used for</li>
<li>What you need to know before you take Pifeltro</li>
<li>How to take Pifeltro</li>
<li>Possible side effects</li>
<li>How to store Pifeltro</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What pifeltro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What pifeltro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Pifeltro is
Pifeltro is used to treat HIV ( human immunodeficiency virus ) infection. It belongs to a group of
medicines called  antiretroviral medicines .
Pifeltro contains the active substance doravirine - a non-nucleoside reverse transcriptase inhibitor
(NNRTI).
What Pifeltro is used for
Pifeltro is used to treat HIV infection in adults, and adolescents aged 12 years and older weighing at
least 35 kg. HIV is the virus that causes AIDS ( acquired immune deficiency syndrome ). You should
not take Pifeltro if your doctor has told you that the virus causing your infection is resistant to
doravirine.
Pifeltro must be used in combination with other medicines for HIV.
How Pifeltro works
When used with other medicines, Pifeltro works by preventing HIV from making more viruses in your
body. This will help by:
* reducing the amount of HIV in your blood (this is called your  viral load )
* increasing the number of white blood cells called  CD4+ T . This can make your immune
system stronger. This may reduce your risk of early death or catching infections because your
immune system is weak.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take pifeltro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take pifeltro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Pifeltro
* if you are allergic to doravirine or any of the other ingredients of this medicine listed in
section 6. * if you are taking the following medicines:
  carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for seizures)
  rifampicin, rifapentine (medicines for tuberculosis)
  St. John s wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or
products that contain it
  mitotane (a medicine to treat cancer)
  enzalutamide (a medicine to treat prostate cancer)
  lumacaftor (a medicine to treat cystic fibrosis)
Do not take Pifeltro if the above applies to you. If you are not sure, talk to your doctor, pharmacist, or
nurse before taking Pifeltro. See also  Other Medicines and Pifeltro  section.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before taking Pifeltro.
Immune reactivation syndrome
This can happen when you start taking any HIV medicine, including this medicine. Your immune
system may get stronger and begin to fight infections that have been hidden in your body for a long
time. Tell your doctor right away if you start having any new symptoms after starting your HIV
medicine.
Autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue)
may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. If you notice any symptoms of infection
or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up
towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor
immediately to seek necessary treatment.
Children and adolescents
Do not give this medicine to children aged less than 12 years or weighing less than 35 kg. The use
of Pifeltro in children aged less than 12 years or weighing less than 35 kg has not yet been studied.
Other medicines and Pifeltro
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken or might take any other
medicines. This is because other medicines may affect how Pifeltro works, and Pifeltro might affect
the way some other medicines work.
There are some medicines you must not take with Pifeltro. See list under  Do not take Pifeltro 
section.
Talk to your doctor before taking the following medicines with Pifeltro, as your doctor may need to
change the dose of your medicines:
* bosentan (a medicine to treat lung disease)
* dabrafenib (a medicine to treat skin cancer)
* lesinurad (a medicine to treat gout)
* modafinil (a medicine to treat excessive sleepiness)
* nafcillin (a medicine to treat some bacterial infections)
* rifabutin (a medicine to treat some bacterial infections such as tuberculosis)
* telotristat ethyl (a medicine to treat diarrhoea in people with carcinoid syndrome)
* thioridazine (a medicine to treat psychiatric conditions such as schizophrenia)
If your doctor decides you should take these medicines with Pifeltro, one tablet of doravirine should be
taken twice daily (approximately 12 hours apart).
Your doctor may check your blood levels or monitor for side effects if you take the following
medicines with Pifeltro:
* sirolimus (a medicine used to control your body s immune response after a transplant)
* tacrolimus (a medicine used to control your body s immune response after a transplant)
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, talk
to your doctor about the risks and benefits of taking Pifeltro. It is preferable to avoid the use of this
medicine during pregnancy. This is because it has not been studied in pregnancy and it is not known if
it will harm your baby while you are pregnant.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed
on to the baby in breast milk.
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as
soon as possible.
Driving and using machines
Use caution when driving or riding a bicycle, or operating machines if you feel dizzy, tired, or sleepy
after taking this medicine.
Pifeltro tablets contain lactose
If you have been told by your doctor that you have an intolerance to lactose, talk to your doctor before
taking this medicine.</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take pifeltro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take pifeltro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. Check with your
doctor, pharmacist, or nurse if you are not sure. This medicine must be used in combination with other
medicines for HIV.
How much to take
The recommended dose is 1 tablet once a day. If you take certain medicines, your doctor may need to
change the amount of doravirine you take. See  Other medicines and Pifeltro  section for a list of
medicines.
Taking this medicine
* Swallow the tablet whole (do not crush or chew).
* This medicine can be taken with food or between meals.
If you take more Pifeltro than you should
Do not take more than the recommended dose. If you accidentally take more, contact your doctor.
If you forget to take Pifeltro
* It is important that you do not miss or skip doses of this medicine.
* If you forget to take a dose, take it as soon as you remember. But if your next dose is due within
12 hours, skip the dose you missed and take the next one at the usual time. Then continue your
treatment as before.
* Do not take a double dose to make up for a missed dose.
* If you are not sure what to do, call your doctor or pharmacist.
If you stop taking Pifeltro
Do not run out of this medicine. Refill your prescription or talk to your doctor before it is all gone.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Do not
stop taking this medicine without first talking to your doctor.
Common: may affect up to 1 in 10 people:
* abnormal dreams, difficulty in sleeping (insomnia)
* headache, dizziness, sleepiness
* feeling sick (nausea), diarrhoea, stomach pain, vomiting, wind (flatulence)
* rash
* feeling tired
Blood tests may also show:
* increased levels of liver enzymes (ALT)
Uncommon: may affect up to 1 in 100 people:
* nightmares, depression, anxiety, irritability, confusion, suicidal thoughts
* trouble concentrating, memory problems, tingling of hands and feet, stiff muscles, poor quality
sleep
* high blood pressure
* constipation, stomach discomfort, swollen or bloated stomach (abdominal distension),
indigestion, soft stools, stomach spasms
* itchiness
* muscle pain, joint pain
* feeling weak, general feeling of being unwell
Blood tests may also show:
* decreased levels of phosphate
* increased levels of liver enzymes (AST)
* increased levels of lipase
* increased levels of amylase
* decreased levels of haemoglobin
Rare: may affect up to 1 in 1 000 people:
* aggression, hallucinations, difficulty adjusting to changes, mood changes, sleep walking
* difficulty breathing, enlarged tonsils
* feeling of incomplete defecation
* inflammation of the skin due to allergy, redness on the cheeks, nose, chin or forehead, bumps or
pimples on the face
* kidney damage, kidney problems, kidney stones
* pain in the chest, feeling cold, pain, thirst
Blood tests may also show:
* decreased levels of magnesium
* increased levels of creatine phosphokinase
Reporting of side effects
If you get any side effects, talk to your doctor,pharmacist, or nurse. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via the national reporting
system listed in Appendix V. By reporting side effects, you can help provide more information on the
safety of this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store pifeltro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store pifeltro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>Keep this medicine out of the sight and reach of children.</li>
<li>Do not use this medicine after the expiry date which is stated on the bottle after EXP. This
medicine should be used within 35 days after first opening of the bottle.</li>
<li>The bottle contains a desiccant protecting the tablets from moisture. Keep the desiccant inside
the bottle and do not throw away until you have finished taking all of the medicine.</li>
<li>Keep the bottle tightly closed in order to protect from moisture.</li>
<li>This medicinal product does not require any special temperature storage conditions.</li>
<li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect the
environment.</li>
</ul> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Pifeltro contains
* The active substance is doravirine 100 mg.
* The other ingredients are croscarmellose sodium E468; hypromellose acetate succinate; lactose
monohydrate; magnesium stearate E470b; microcrystalline cellulose E460; and silica, colloidal
anhydrous E551. The tablets are film-coated with a coating material containing the following
ingredients: carnauba wax E903; hypromellose E464; lactose monohydrate; titanium dioxide
E171; and triacetin E1518. What Pifeltro looks like and contents of the pack
Pifeltro is available as a white, oval-shaped, film-coated tablet, and is debossed with the corporate
logo and 700 on one side and plain on the other side.
The following pack sizes are available:
* 1 bottle with 30 film-coated tablets
* 90 film-coated tablets (3 bottles of 30 film-coated tablets)
Not all pack sizes may be available in your country.
Marketing Authorisation Holder and Manufacturer
Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
For any information about this medicine, please contact the local representative of the Marketing
Authorisation Holder:
Belgi /Belgique/Belgien
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 msd_lietuva@merck.com</p>
<p>.: +359 2 819 3info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
T l/Tel: +32(0)27766dpoc_belux@merck.com
 esk  republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarorsz g
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf: + 45 4482 4dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme O 
Tel.: +372 6144 msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 msdnorge@msd.no</p>
<p>MSD  . . . . .
 : +30 210 98 97 dpoc_greece@merck.com
 sterreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 dpoc_austria@merck.com
Espa a
Merck Sharp &amp; Dohme de Espa a, S.A.
Tel: +34 91 321 06 msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 msdpolska@merck.com
France
MSD France
T l: + 33 (0) 1 80 46 40 Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465inform_pt@merck.com
Hrvatska:
Merck Sharp &amp; Dohme d.o.o. 
Tel: + 385 1 6611 croatia_info@merck.com 
Rom nia
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila
d.o.o.
Tel: +386 1 5204 msd.slovenia@merck.com
 sland
Vistor hf.
S mi: + 354 535 7Slovensk  republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 info@msd.fi</p>
<p>Merck Sharp &amp; Dohme Cyprus Limited
 .: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700medicinskinfo@merck.com
Latvija
SIA Merck Sharp &amp; Dohme Latvija
Tel: + 371 67364msd_lv@merck.com
United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998medinfoNI@msd.com
This leaflet was last revised in {MM/YYYY}
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu .</p> </div>"""      



Instance: composition-da-d9e1f5caf32113b1e6722af1d88782c1
InstanceOf: CompositionUvEpi
Title: "Composition for pifeltro Package Leaflet"
Description:  "Composition for pifeltro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/18/1332/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd9e1f5caf32113b1e6722af1d88782c1)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - pifeltro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Pifeltro
3. Sådan skal du tage Pifeltro
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What pifeltro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What pifeltro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Pifeltro er
Pifeltro anvendes til behandling af infektion med hiv (‘humant immundefekt-virus’). Det tilhører en
gruppe af lægemidler, der kaldes ‘antiretrovirale lægemidler’.
Pifeltro indeholder det aktive stof doravirin - en non-nukleosid revers transkriptasehæmmer (NNRTI).
Anvendelse
Pifeltro anvendes til behandling af hiv-infektion hos voksne og unge i alderen 12 år og derover, som
vejer mindst 35 kg. Hiv er det virus, der forårsager aids (‘erhvervet immundefektsyndrom’). Du må
ikke tage Pifeltro, hvis lægen har fortalt dig, at det virus, som forårsager din infektion, er resistent
(modstandsdygtigt) over for doravirin.
Pifeltro skal anvendes i kombination med andre lægemidler mod hiv.
Virkning
Når Pifeltro anvendes sammen med andre lægemidler, virker det ved at hæmme hiv-virusets evne til at
formere sig (lave kopier af sig selv) i kroppen. Dette hjælper med at:</p>
<ul>
<li>
<p>nedsætte mængden af hiv i dit blod (dette kaldes din ‘virusmængde’)</p>
</li>
<li>
<p>øge antallet af en slags hvide blodlegemer, der kaldes ‘CD4+ T-celler’. Dette kan gøre dit
immunforsvar stærkere og kan nedsætte din risiko for tidlig død eller for at få infektioner, som
følge af at dit immunforsvar er svækket.
37</p>
</li>
</ul> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take pifeltro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take pifeltro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Pifeltro</p>
<ul>
<li>
<p>hvis du er allergisk over for doravirin eller et af de øvrige indholdsstoffer i Pifeltro (angivet i
punkt 6) </p>
</li>
<li>
<p>hvis du tager et eller flere af følgende lægemidler:</p>
</li>
<li>
<p>carbamazepin, oxcarbazepin, phenobarbital, phenytoin (lægemidler mod krampeanfald)</p>
</li>
<li>rifampicin, rifapentin (lægemidler mod tuberkulose)</li>
<li>perikon (Hypericum perforatum, et naturlægemiddel mod depression og angst) eller
lægemidler, der indeholder perikon</li>
<li>mitotan (et lægemiddel til behandling af kræft)</li>
<li>enzalutamid (et lægemiddel til behandling af prostatakræft)</li>
<li>
<p>lumacaftor (et lægemiddel til behandling af cystisk fibrose).
Tag ikke Pifeltro, hvis ovenstående gælder for dig. Hvis du er i tvivl, så kontakt lægen,
apotekspersonalet eller sundhedspersonalet, før du tager Pifeltro. Se også punktet “Brug af andre
lægemidler sammen med Pifeltro".
Advarsler og forsigtighedsregler
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Pifeltro.
Immunreaktiveringssyndrom
Dette kan opstå, når du begynder at tage en hvilken som helst hiv-medicin, herunder dette lægemiddel.
Dit immunforsvar kan blive stærkere og begynde at bekæmpe infektioner, der har været skjult i din
krop i lang tid. Fortæl det straks til lægen, hvis du begynder at få nye symptomer, efter at du er startet
med din hiv-medicin.
Autoimmune sygdomme (skyldes, at immunsystemet angriber sundt kropsvæv) kan også opstå, efter
du er begyndt at tage medicin til behandling af din hiv-infektion. Autoimmune sygdomme kan opstå
mange måneder efter, du er påbegyndt behandling. Du skal straks informere din læge for at få den
nødvendige behandling, hvis du bemærker symptomer på infektion eller andre symptomer såsom
muskelsvaghed, svaghed begyndende i hænder og fødder, og som bevæger sig op igennem kroppen,
hjertebanken, rysten eller hyperaktivitet.
Børn og unge
Dette lægemiddel må ikke anvendes til børn under 12 år eller børn, som vejer under 35 kg.
Anvendelse af Pifeltro til børn under 12 år eller børn, som vejer under 35 kg, er endnu ikke undersøgt.
Brug af andre lægemidler sammen med Pifeltro
Fortæl lægen, apotekspersonalet eller sygeplejersken, hvis du tager andre lægemidler, for nylig har
taget andre lægemidler eller planlægger at tage andre lægemidler. Årsagen er, at andre lægemidler kan
påvirke, hvordan Pifeltro virker, og Pifeltro kan påvirke, hvordan andre lægemidler virker.
Der er visse lægemidler, som du ikke må tage sammen med Pifeltro. Se listen under punktet “Tag ikke
Pifeltro".
38
Kontakt lægen, før du tager følgende lægemidler sammen med Pifeltro, da lægen kan blive nødt til at
ændre på dosis af din medicin:</p>
</li>
<li>
<p>bosentan (et lægemiddel til behandling af lungesygdom)</p>
</li>
<li>
<p>dabrafenib (et lægemiddel til behandling af hudkræft)</p>
</li>
<li>
<p>lesinurad (et lægemiddel til behandling af urinsyregigt)</p>
</li>
<li>
<p>modafinil (et lægemiddel til behandling af overdreven søvnighed)</p>
</li>
<li>
<p>nafcillin (et lægemiddel til behandling af visse bakterieinfektioner)</p>
</li>
<li>
<p>rifabutin (et lægemiddel til behandling af visse bakterieinfektioner, f.eks. tuberkulose)</p>
</li>
<li>
<p>telotristatethyl (et lægemiddel til behandling af diarré hos personer med karcinoidsyndrom)</p>
</li>
<li>
<p>thioridazin (et lægemiddel til behandling af psykiske lidelser såsom skizofreni).
Hvis lægen beslutter, at du skal tage disse lægemidler sammen med Pifeltro, skal du tage 1 tablet
Pifeltro to gange dagligt (med ca. 12 timers mellemrum).
Det kan være nødvendigt for lægen at kontrollere medicinindholdet i blodet eller holde øje med, om du
får bivirkninger, hvis du tager følgende lægemidler sammen med Pifeltro:</p>
</li>
<li>
<p>sirolimus (et lægemiddel, der anvendes til at kontrollere din krops immunrespons efter en
transplantation)</p>
</li>
<li>
<p>tacrolimus (et lægemiddel, der anvendes til at kontrollere din krops immunrespons efter en
transplantation).
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal
du spørge lægen til råds om risici og fordele ved at tage Pifeltro. Det bør undgås at anvende dette
lægemiddel under graviditet. Dette skyldes, at det ikke er undersøgt under graviditet, og det er ukendt,
om det kan skade dit ufødte barn, mens du er gravid.
Amning anbefales ikke hos kvinder, der er hiv-positive, da hiv-infektion kan overføres til barnet
gennem modermælken.
Hvis du ammer eller påtænker at amme, bør du drøfte det med lægen hurtigst muligt.
Trafik- og arbejdssikkerhed
Vær forsigtig, når du fører motorkøretøj, kører på cykel eller betjener maskiner, hvis du føler dig
svimmel, træt eller søvnig, efter at du har taget dette lægemiddel.
Pifeltro indeholder lactose
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse
sukkerarter (lactose).</p>
</li>
</ul> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take pifeltro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take pifeltro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens, apotekspersonalets eller sygeplejerskens anvisning. Er du i
tvivl, så spørg lægen, apotekspersonalet eller sygeplejersken. Lægemidlet skal anvendes i kombination
med andre lægemidler mod hiv.
Så meget skal du tage
Den anbefalede dosis er 1 tablet en gang dagligt. Hvis du tager visse lægemidler, kan lægen blive nødt
til at ændre den mængde doravirin, du tager. Se punktet “Brug af andre lægemidler sammen med
Pifeltro" for en liste over lægemidler.
Sådan skal du tage dette lægemiddel</p>
<ul>
<li>
<p>Slug tabletten hel (du må ikke knuse eller tygge tabletten).</p>
</li>
<li>
<p>Dette lægemiddel kan tages med mad eller mellem måltiderne.
39
Hvis du har taget for meget Pifeltro
Du må ikke tage mere end den anbefalede dosis. Hvis du kommer til at tage mere, skal du kontakte
lægen.
Hvis du har glemt at tage Pifeltro</p>
</li>
<li>
<p>Det er vigtigt, at du ikke glemmer eller springer doser af dette lægemiddel over.</p>
</li>
<li>
<p>Hvis du glemmer at tage en dosis, skal du tage den, så snart du kommer i tanke om det. Hvis din
næste dosis imidlertid skal tages inden for 12 timer, så spring den glemte dosis over, og tag den
næste dosis på det sædvanlige tidspunkt. Fortsæt herefter din behandling som før.</p>
</li>
<li>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.</p>
</li>
<li>
<p>Hvis du er i tvivl om, hvad du skal gøre, skal du kontakte lægen eller apotekspersonalet.
Hvis du holder op med at tage Pifeltro
Sørg for ikke at løbe tør for dette lægemiddel. Forny din recept, eller kontakt lægen, inden du løber
tør.
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.</p>
</li>
</ul> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. Du
må ikke holde op med at tage dette lægemiddel uden først at have talt med lægen.
Almindelig: kan forekomme hos op til 1 ud af 10 personer:</p>
<ul>
<li>
<p>unormale drømme, søvnbesvær (søvnløshed)</p>
</li>
<li>
<p>hovedpine, svimmelhed, søvnighed</p>
</li>
<li>
<p>kvalme, diarré, mavesmerter, opkastning, luft i maven (flatulens)</p>
</li>
<li>
<p>udslæt</p>
</li>
<li>
<p>træthedsfølelse.
Blodprøver kan også vise:</p>
</li>
<li>
<p>øget indhold af leverenzymer (ALAT).
Ikke almindelig: kan forekomme hos op til 1 ud af 100 personer:</p>
</li>
<li>
<p>mareridt, depression, angst, irritabilitet, forvirring, selvmordstanker</p>
</li>
<li>
<p>koncentrationsbesvær, hukommelsesproblemer, prikken og snurren i hænder og fødder,
muskelstivhed, dårlig søvnkvalitet</p>
</li>
<li>
<p>højt blodtryk</p>
</li>
<li>
<p>forstoppelse, mavegener, hævet eller oppustet mave (abdominal distension),
fordøjelsesproblemer, blød afføring, mavekramper  </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>muskelsmerter, ledsmerter</p>
</li>
<li>
<p>svaghedsfølelse, generel følelse af ubehag.
Blodprøver kan også vise:</p>
</li>
<li>
<p>nedsat indhold af fosfat</p>
</li>
<li>
<p>forhøjet indhold af leverenzymer (ASAT)</p>
</li>
<li>
<p>forhøjet indhold af lipase</p>
</li>
<li>
<p>forhøjet indhold af amylase </p>
</li>
<li>
<p>nedsat indhold af hæmoglobin. 
Sjælden: kan forekomme hos op til 1 ud af 1 000 personer:</p>
</li>
<li>
<p>aggression, hallucinationer, besvær med at tilpasse sig forandringer, humørsvingninger,
søvngængeri</p>
</li>
<li>
<p>vejrtrækningsproblemer, forstørrede mandler
40</p>
</li>
<li>
<p>følelse af ufuldstændig tømning efter afføring</p>
</li>
<li>
<p>inflammation i huden på grund af allergi, rødme på kinder, næse, hage eller pande, buler eller
bumser i ansigtet</p>
</li>
<li>
<p>nyreskade, nyreproblemer, nyresten</p>
</li>
<li>
<p>brystsmerter, kuldefølelse, smerter, tørst.
Blodprøver kan også vise:</p>
</li>
<li>
<p>nedsat indhold af magnesium</p>
</li>
<li>
<p>forhøjet indhold af kreatinfosfokinase.
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med lægen, apotekspersonalet eller sygeplejersken. Dette
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere
information om sikkerheden af dette lægemiddel.</p>
</li>
</ul> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store pifeltro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store pifeltro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <ul>
<li>
<p>Opbevar lægemidlet utilgængeligt for børn.</p>
</li>
<li>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på flasken efter EXP. Lægemidlet skal
anvendes inden for 35 dage efter første åbning af flasken.</p>
</li>
<li>
<p>Flasken indeholder et tørremiddel, som beskytter tabletterne mod fugt. Lad tørremidlet blive i
flasken og lad være med at kassere det, før du er færdig med at tage al medicinen. </p>
</li>
<li>
<p>Hold flasken tæt tillukket for at beskytte mod fugt.</p>
</li>
<li>
<p>Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel.</p>
</li>
<li>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må
du ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.</p>
</li>
</ul> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pifeltro indeholder:</p>
<ul>
<li>
<p>Aktivt stof: doravirin 100 mg.</p>
</li>
<li>
<p>Øvrige indholdsstoffer: croscarmellosenatrium (E468), hypromelloseacetatsuccinat,
lactosemonohydrat, magnesiumstearat (E470b), mikrokrystallinsk cellulose (E460) og silica,
kolloid vandfri (E551). Tabletterne er filmovertrukket med et overtræksmateriale med følgende
indholdsstoffer: carnaubavoks (E903), hypromellose (E464), lactosemonohydrat, titandioxid
(E171) og triacetin (E1518).
Udseende og pakningsstørrelser
Pifeltro fås som en hvid, oval, filmovertrukken tablet med virksomhedslogo og 700 præget på den ene
side og uden prægning på den anden side.
Følgende pakningsstørrelser er tilgængelige:</p>
</li>
<li>
<p>1 flaske med 30 filmovertrukne tabletter</p>
</li>
<li>
<p>90 filmovertrukne tabletter (3 flasker a 30 filmovertrukne tabletter).
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen og fremstiller
Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Holland
41
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
MSD Belgium
Tél/Tel: 32(0)27766211
dpoc_belux@merck.com
Lietuva
UAB Merck Sharp &amp; Dohme
Tel. + 370 5 278 02 47
msd_lietuva@merck.com
България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com
Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@merck.com
Česká republika
Merck Sharp &amp; Dohme s.r.o.
Tel: +420 233 010 dpoc_czechslovak@merck.com
Magyarország
MSD Pharma Hungary Kft. 
Tel.: +36 1 888 5300
hungary_msd@merck.com
Danmark
MSD Danmark ApS
Tlf.: + 45 4482 4000
dkmail@merck.com
Malta
Merck Sharp &amp; Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com
Deutschland
MSD Sharp &amp; Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de
Nederland
Merck Sharp &amp; Dohme B.V.
Tel: 0800 9999(+31 23 5153153)
medicalinfo.nl@merck.com
Eesti
Merck Sharp &amp; Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com
Norge
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no
Ελλάδα
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc_greece@merck.com
Österreich
Merck Sharp &amp; Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@merck.com
España
Merck Sharp &amp; Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com
Polska
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 00
msdpolska@merck.com
France
MSD France
Tél: + 33 (0) 1 80 46 40 40
Portugal
Merck Sharp &amp; Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com
42
Hrvatska
Merck Sharp &amp; Dohme d.o.o. 
Tel: + 385 1 6611 333
croatia_info@merck.com 
România
Merck Sharp &amp; Dohme Romania S.R.L.
Tel: +40 21 529 29 00
msdromania@merck.com
Ireland
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfo_ireland@merck.com
Slovenija
Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
msd.slovenia@merck.com
Ísland
Vistor hf.
Sími: + 354 535 7000
Slovenská republika
Merck Sharp &amp; Dohme, s. r. o.
Tel: +421 2 58282010
dpoc_czechslovak@merck.com
Italia
MSD Italia S.r.l. 
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com
Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi
Κύπρος
Merck Sharp &amp; Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
cyprus_info@merck.com
Sverige
Merck Sharp &amp; Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@merck.com
Latvija 
SIA Merck Sharp &amp; Dohme Latvija 
Tel: + 371 67364msd_lv@merck.com </p>
</li>
</ul>
<p>United Kingdom (Northern Ireland)
Merck Sharp &amp; Dohme Ireland (Human Health)
Limited
Tel: +353 (0)1 2998700
medinfoNI@msd.com
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.</p> </div>"""      





                    
Instance: bundlepackageleaflet-en-d9e1f5caf32113b1e6722af1d88782c1
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for pifeltro Package Leaflet for language en"
Description: "ePI document Bundle for pifeltro Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d9e1f5caf32113b1e6722af1d88782c1"
* entry[0].resource = composition-en-d9e1f5caf32113b1e6722af1d88782c1

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd9e1f5caf32113b1e6722af1d88782c1"
* entry[=].resource = mpd9e1f5caf32113b1e6722af1d88782c1
                            
                    
Instance: bundlepackageleaflet-da-d9e1f5caf32113b1e6722af1d88782c1
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for pifeltro Package Leaflet for language da"
Description: "ePI document Bundle for pifeltro Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d9e1f5caf32113b1e6722af1d88782c1"
* entry[0].resource = composition-da-d9e1f5caf32113b1e6722af1d88782c1

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd9e1f5caf32113b1e6722af1d88782c1"
* entry[=].resource = mpd9e1f5caf32113b1e6722af1d88782c1
                            
                    



Instance: mpd9e1f5caf32113b1e6722af1d88782c1
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Pifeltro 100 mg film-coated tablets"
Description: "Pifeltro 100 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1332/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Pifeltro 100 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: d9e1f5caf32113b1e6722af1d88782c1ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "pifeltro"

* status = #current
* mode = #working

* title = "List of all ePIs associated with pifeltro"

* subject = Reference(mpd9e1f5caf32113b1e6722af1d88782c1)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#pifeltro "pifeltro"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d9e1f5caf32113b1e6722af1d88782c1) // pifeltro en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d9e1f5caf32113b1e6722af1d88782c1) // pifeltro da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d9e1f5caf32113b1e6722af1d88782c1
InstanceOf: List

* insert d9e1f5caf32113b1e6722af1d88782c1ListRuleset
    